
Jordan D. Berlin, M.D.
- Associate Director for Clinical Research
- Ingram Professor of Cancer Research
- Interim Division Director for Hematology and Oncology
- Professor of Medicine (Hematology/Oncology)
- Director, Phase I Program
Phone
2220 Pierce Avenue
777 Preston Building
Nashville, TN 37232-6307
Jordan D. Berlin, M.D.
- Associate Director for Clinical Research
- Ingram Professor of Cancer Research
- Interim Division Director for Hematology and Oncology
- Professor of Medicine (Hematology/Oncology)
- Director, Phase I Program
615-936-8580
jordan.berlin@vumc.org
2220 Pierce Avenue
777 Preston Building
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Jordan Berlin, M.D, is a medical oncologist who specializes in gastrointestinal cancers and investigational drug development (Phase I). In his roles as the Associate Director for Clinical Research and Director of Phase I Research at the Vanderbilt-Ingram Cancer Center, Dr. Berlin serves to coordinate clinical and translational efforts across the cancer center from the research programs to the phase I program as well as from within the VICC research programs. He is responsible for advancing preclinical data and investigational drugs to investigator-initiated trials and clinical evaluation. Dr. Berlin has extensive experience designing investigator-initiated and cooperative group trials as well as experience advising the pharmaceutical industry on trial design and development. Dr. Berlin is the PI of the VICC National Clinical Trials Network Lead Academic Participating Site Grant and the VICC PI of the VIKTriY multi-site UM1 grant led overall by Pat LoRusso at Yale Cancer Center. Additionally, as the immediate-past Medical Director of the Clinical Trials Office (CTO), he mentors several junior investigators in phase I and GI malignancies and continues to mentor Vicki Keedy, M.D. in her role as current Medical Director of the CTO.
Education
- B.S. (Biochemistry), University of Illinois (1985)
- M.D., University of Illinois, (1989)
- Internship/Residency - Internal Medicine, University of Cincinnati Hospital (1992)
- Fellowship, University of Wisconsin Hospital and Clinics; University of Cincinnati Hospital (1995)
Research Emphasis
Research Description
Publications
- Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.
- Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist [print-electronic]. 2017 Jun 6/7/2017; PMID: 28592615, PII: theoncologist.2017-0175, DOI: 10.1634/theoncologist.2017-0175, ISSN: 1549-490X.
- Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS. A phase 1 study of anti-TGFß receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol [print-electronic]. 2017 Apr; 79(4): 673-80. PMID: 28280971, PII: 10.1007/s00280-017-3245-5, DOI: 10.1007/s00280-017-3245-5, ISSN: 1432-0843.
- Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP. Academic Cancer Center Phase I Program Development. Oncologist [print-electronic]. 2017 Apr; 22(4): 369-74. PMID: 28314841, PMCID: PMC5388388, PII: theoncologist.2016-0409, DOI: 10.1634/theoncologist.2016-0409, ISSN: 1549-490X.
- Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.
- Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?. Pancreas. 2017 Feb; 46(2): 143-50. PMID: 28085753, PMCID: PMC5242389, PII: 00006676-201702000-00002, DOI: 10.1097/MPA.0000000000000753, ISSN: 1536-4828.
- Rahib L, Fleshman JM, Matrisian LM, Berlin JD. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. JAMA Oncol. 2016 Sep 9/1/2016; 2(9): 1209-16. PMID: 27270617, PII: 2527367, DOI: 10.1001/jamaoncol.2016.0585, ISSN: 2374-2445.
- Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin. Cancer Res [print-electronic]. 2016 May 5/1/2016; 22(9): 2146-54. PMID: 26655846, PII: 1078-0432.CCR-15-1622, DOI: 10.1158/1078-0432.CCR-15-1622, ISSN: 1078-0432.
- Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol [print-electronic]. 2016 May; 119(2): 312-8. PMID: 27106554, PMCID: PMC4961249, PII: S0167-8140(16)31047-7, DOI: 10.1016/j.radonc.2016.04.013, ISSN: 1879-0887.
- Matrisian LM, Berlin JD. The Past, Present, and Future of Pancreatic Cancer Clinical Trials. Am Soc Clin Oncol Educ Book. 2016; 35: e205-15. PMID: 27249725, PII: 159117, DOI: 10.14694/EDBK_159117, ISSN: 1548-8756.